Fundraising FoxPivotal Life Sciences — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Rallybio is a clinical-stage biotechnology company developing therapies for severe and rare diseases, with a lead program in RLYB116, a C5 complement inhibitor in clinical development, and a preclinical program in RLYB332, a matriptase-2 antibody for iron overload disorders.
HealthtechFarmington, US
Jeffrey M. Fryer(Executive Officer, Director)Martin W. Mackay(Executive Officer, Director)Stephen Uden(Executive Officer, Director)
Board seatRob Hopfner· per SEC Form D
Co-investors5AM VenturesCanaan Partners
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.
BiotechHealthtechLongevityRichmond, US
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Executive Officer, Director)inEric Morgen(Director)inDov Goldstein(Executive Officer)in
BoardPatrick Enright(Director)in
Co-investorsAndreessen HorowitzElad GilFelicis VenturesIA Seed VenturesLongitude CapitalOrbiMed+19 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.